Literature DB >> 19429811

IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice.

Qianli Yu1, Randy Vazquez, Elham Vali Khojeini, Chirag Patel, Raj Venkataramani, Douglas F Larson.   

Abstract

Osteopontin (OPN), a key component of the extracellular matrix, is associated with the fibrotic process during tissue remodeling. OPN and the cytokine interleukin (IL)-18 have been shown to be overexpressed in an array of human cardiac pathologies. In the present study, we determined the role of IL-18 in the regulation of cardiac OPN expression and the subsequent interstitial fibrosis and diastolic dysfunction. We demonstrated parallel increases in IL-18, OPN expression, and interstitial fibrosis in murine models of left ventricular pressure and volume overload. Exogenous recombinant (r)IL-18 administered for 2 wk increased cardiac OPN expression, interstitial fibrosis, and diastolic dysfunction. Stimulation of the T helper (Th)1 lymphocyte phenotype with a selective toll-like receptor (TLR)9 agonist induced cardiac IL-18 and OPN expression, which was associated with increased cardiac fibrillar collagen concentrations and interstitial fibrosis resulting in diastolic dysfunction. rIL-18 induced OPN expression and protein levels in primary of cardiac fibroblast cultures. Conditioned media from TLR9-stimulated T lymphocyte cultures induced IL-18 and OPN expression in cardiac fibroblasts, while blockade of the IL-18 receptor with a neutralizing antibody abolished the increase in OPN expression. Furthermore, a mutation in the transcriptional factor interferon regulatory factor (IRF)1 or IRF1 small interfering RNA (siRNA) resulted in the decreased expression of IL-18 and OPN in cardiac fibroblasts. With pressure overload, IRF1-mutant mice showed downregulation of IL-18 and OPN expression in cardiac tissue, reduced cardiac fibrotic development, and increased left ventricular function compared with wild type. These results provide direct evidence that the induction of IL-18 regulates OPN-mediated cardiac fibrosis and diastolic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429811      PMCID: PMC2711747          DOI: 10.1152/ajpheart.01285.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  46 in total

1.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.

Authors:  S Ashkar; G F Weber; V Panoutsakopoulou; M E Sanchirico; M Jansson; S Zawaideh; S R Rittling; D T Denhardt; M J Glimcher; H Cantor
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

2.  CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.

Authors:  D M Klinman; A K Yi; S L Beaucage; J Conover; A M Krieg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

Review 3.  Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts.

Authors:  G W Booz; K M Baker
Journal:  Cardiovasc Res       Date:  1995-10       Impact factor: 10.787

4.  Myocardial osteopontin expression is associated with left ventricular hypertrophy.

Authors:  K Graf; Y S Do; N Ashizawa; W P Meehan; C M Giachelli; C C Marboe; E Fleck; W A Hsueh
Journal:  Circulation       Date:  1997-11-04       Impact factor: 29.690

5.  Age-related left ventricular function in the mouse: analysis based on in vivo pressure-volume relationships.

Authors:  B Yang; D F Larson; R Watson
Journal:  Am J Physiol       Date:  1999-11

6.  Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice.

Authors:  Zhonglin Xie; Mahipal Singh; Krishna Singh
Journal:  Hypertension       Date:  2004-11-08       Impact factor: 10.190

7.  Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction.

Authors:  N Ashizawa; K Graf; Y S Do; T Nunohiro; C M Giachelli; W P Meehan; T L Tuan; W A Hsueh
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

8.  Simple, rapid, and effective method of producing aortocaval shunts in the rat.

Authors:  R Garcia; S Diebold
Journal:  Cardiovasc Res       Date:  1990-05       Impact factor: 10.787

9.  Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes.

Authors:  Bysani Chandrasekar; Srinivas Mummidi; William C Claycomb; Ruben Mestril; Mona Nemer
Journal:  J Biol Chem       Date:  2004-12-01       Impact factor: 5.157

10.  Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure.

Authors:  Ziad Mallat; Christophe Heymes; Anne Corbaz; Damien Logeart; Sami Alouani; Alain Cohen-Solal; Tim Seidler; Gerd Hasenfuss; Yolande Chvatchko; Ajay M Shah; Alain Tedgui
Journal:  FASEB J       Date:  2004-09-15       Impact factor: 5.191

View more
  33 in total

1.  EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling.

Authors:  Balachandar Venkatesan; Anthony J Valente; Sumanth D Prabhu; Prakashsrinivasan Shanmugam; Patrice Delafontaine; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2010-06-09       Impact factor: 5.000

2.  Low-level transcutaneous vagus nerve stimulation attenuates cardiac remodelling in a rat model of heart failure with preserved ejection fraction.

Authors:  Liping Zhou; Adrian Filiberti; Mary Beth Humphrey; Christian D Fleming; Benjamin J Scherlag; Sunny S Po; Stavros Stavrakis
Journal:  Exp Physiol       Date:  2018-11-29       Impact factor: 2.969

3.  Role of Interleukin-1 in Radiation-Induced Cardiomyopathy.

Authors:  Eleonora Mezzaroma; Ross B Mikkelsen; Stefano Toldo; Adolfo G Mauro; Khushboo Sharma; Carlo Marchetti; Asim Alam; Benjamin W Van Tassell; David A Gewirtz; Antonio Abbate
Journal:  Mol Med       Date:  2015-03-26       Impact factor: 6.354

4.  Effects of interleukin-18 on cardiac fibroblast function and gene expression.

Authors:  Charity Fix; Kellie Bingham; Wayne Carver
Journal:  Cytokine       Date:  2010-11-02       Impact factor: 3.861

Review 5.  Innate immune signaling in cardiac ischemia.

Authors:  Fatih Arslan; Dominique P de Kleijn; Gerard Pasterkamp
Journal:  Nat Rev Cardiol       Date:  2011-03-29       Impact factor: 32.419

6.  Novel mechanisms for caspase inhibition protecting cardiac function with chronic pressure overload.

Authors:  Misun Park; Stephen F Vatner; Lin Yan; Shumin Gao; Seunghun Yoon; Grace Jung Ah Lee; Lai-Hua Xie; Richard N Kitsis; Dorothy E Vatner
Journal:  Basic Res Cardiol       Date:  2013-01-01       Impact factor: 17.165

Review 7.  Proinflammatory cytokines in heart failure: double-edged swords.

Authors:  Mona Hedayat; Mohammad Jafar Mahmoudi; Noel R Rose; Nima Rezaei
Journal:  Heart Fail Rev       Date:  2010-11       Impact factor: 4.214

Review 8.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

9.  Genetic ablation of interleukin-18 does not attenuate hypobaric hypoxia-induced right ventricular hypertrophy.

Authors:  Danielle R Bruns; Peter M Buttrick; Lori A Walker
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-01-08       Impact factor: 5.464

10.  Pressure overload induces IL-18 and IL-18R expression, but markedly suppresses IL-18BP expression in a rabbit model. IL-18 potentiates TNF-α-induced cardiomyocyte death.

Authors:  Tadashi Yoshida; Ingeborg Friehs; Srinivas Mummidi; Pedro J del Nido; Solange Addulnour-Nakhoul; Patrice Delafontaine; Anthony J Valente; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2014-08-07       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.